Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPFFR1 | Q9GZQ6 | 15/20 | 0.62 |
| ▸ | NPFFR2 | Q9Y5X5 | 15/20 | 0.62 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16926455 | 0.91 | NPFFR1 (0.60) | NPFFR1NPFFR2OPRK1SIGMAR1 | |
| SCHEMBL4508281 | 0.87 | NPFFR1 (0.57) | NPFFR1NPFFR2OPRK1SIGMAR1IDO1 | |
| SCHEMBL14728238 | 0.86 | NPFFR1 (0.64) | NPFFR1NPFFR2SIGMAR1CYP3A4CYP2D6 | |
| SCHEMBL2348786 | 0.86 | NPFFR1 (0.64) | NPFFR1NPFFR2SIGMAR1CYP2D6IDO1 | |
| SCHEMBL4502727 | 0.85 | NPFFR1 (0.56) | NPFFR1NPFFR2OPRK1SIGMAR1CYP3A4 | |
| SCHEMBL20572136 | 0.84 | NPFFR1 (0.60) | NPFFR1NPFFR2OPRK1CYP2D6 | |
| SCHEMBL22050090 | 0.84 | NPFFR1 (0.62) | NPFFR1NPFFR2SIGMAR1CYP2D6IDO1 | |
| SCHEMBL13320953 | 0.84 | NPFFR1 (0.62) | NPFFR1NPFFR2SIGMAR1 | |
| SCHEMBL31410763 | 0.83 | NPFFR1 (0.54) | NPFFR1NPFFR2SIGMAR1 | |
| SCHEMBL23070812 | 0.82 | NPFFR1 (0.60) | NPFFR1NPFFR2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630770-B1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| US-11591336-B2 | Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors | D. E. SHAW RESEARCH, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| US-20200172546-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS, INC. | 2020-06-04 | — | — | US | disclosed |
| EP-1061076-B1 | N-ACYL CYCLIC AMINE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2004-12-08 | — | — | EP | disclosed |
| EP-1061076-A1 | N-ACYL CYCLIC AMINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2000-12-20 | — | — | EP | disclosed |
| US-6140333-A | FOR TREATMENT AND/OR PROPHYLAXIS OF DISEASES INCLUDE SUCH RESPIRATORY DISEASES AS CHRONIC OBSTRUCTIVE PULMONARY DISEASES, CHRONIC BRONCHITIS, ASTHMA, CHRONIC RESPIRATORY OBSTRUCTION, PULMONARY FIBROSIS, PULMONARY EMPHYSEMA | BANYU PHARMACEUTICAL CO LTD (JP) | 2000-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172546-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | PTPRJ, PTPN2, PTPN5 | NPFFR1 3630/4885NPFFR2 3294/4885OPRK1 4032/4885 |
| US-11591336-B2 | Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors | PTPN5, PTPN2, PTPN1 | NPFFR1 3374/4885NPFFR2 3113/4885OPRK1 4419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.